General BE topics [Design Issues]

posted by DavidManteigas – Portugal, 2017-06-12 12:35 (1405 d 18:53 ago) – Posting: # 17487
Views: 14,696


In my opinion, from my knowledge of the portuguese regulators, there is a lack of members with statistical expertise to properly assess the adequacy of the sample size, or any other question regarding statistical methods, either in Ethics Committees or the regulator.

In my plans for 2018, I will attempt to meet with the portuguese regulator so they can gave me access to their approved studies in bioequivalence in the last years so I can quantify the degree of overpowering of bioequivalence studies when compared to the observed CV and the predicted/guessed/magically obtained predicted CV. My intent is to publish a paper with that information and to sensitize regulators and ethics committees to this issue, which mixes both the sample size calculation and the adequacy of the study design in light of the available information.

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 10 (0 registered, 10 guests [including 3 identified bots]).
Forum time: Sunday 07:28 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz